Sun Pharma announces distribution alliance with Mitsubishi Tanabe Pharma Corporation in Japan Transfer process of marketing authorizations for 14 Rx brands to begin in October

Mumbai & Tokyo, September 20, 2016: Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) today announced the initiation of a phased transfer of manufacturing & marketing rights in Japan for the 14 long-listed/established prescription brands acquired from Novartis. These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma K.K. to Sun Pharma’s subsidiary in Japan beginning October 2016.

Sun Pharma has also signed a strategic distribution alliance with Mitsubishi Tanabe Pharma Corporation for these 14 prescription brands. Under this alliance, following the transfer of manufacturing & marketing rights to Sun Pharma’s subsidiary in Japan, Mitsubishi Tanabe Pharma Corporation will market and distribute all the 14 brands as well as provide information on their proper use to healthcare professionals.

According to Isao Muramatsu, President & Representative Director, Sun Pharma Japan Ltd, Sun Pharma, “Through this alliance we have the opportunity to leverage Mitsubishi Tanabe Pharma Corporation’s specialized expertise to create a strong business foundation for us in Japan. Sun Pharma will focus on expanding its sales channels in Japan’s pharmaceutical market while continuing to ensure a stable supply of medicines and healthcare information.”

The schedule of transfer of these 14 brands is given below:

Date of Transfer: October 20, 2016

Brand name	Generic name	Major indications	Scheduled date of sale
Parlodel®	Bromocriptine mesylate	Parkinson’s syndrome	November 1, 2016
Lamisil®	Terbinafine	Tinea unguium, tinea manuum and pedis, candidiasis
Nitroderm®	Nitroglycerin	Angina pectoris	November 21, 2016

Date of Transfer: November 21, 2016

Brand name	Generic name	Major indications	Scheduled date of sale
Apresoline®	Hydralazine hydrochloride	Essential hypertension	December 1, 2016
Zaditen®	Ketotifen fumarate	Allergic rhinitis
Symmetrel®	Amantadine hydrochloride	Parkinson’s syndrome
Cibacen®	Benazepril hydrochloride	Hypertension
Tegretol®	Carbamazepine	Epilepsy

Pursennid®	Sennosides A and B	Constipation
Lioresal®	Baclofen	Spastic paralysis associated with cerebrovascular disorder
Lopresor®	Metoprolol tartrate	Angina pectoris, achyarrhythmia

Scheduled transfers in 2017

Brand name	Generic name	Major indications	Scheduled date of sale
Ternelin™	Tizanidine hydrochloride	Neck, lumbago Shoulder and arm Syndrome	2017
Ludiomil®	Maprotiline hydrochloride	Depression
Lochol®	Fluvastatin sodium	Hypercholesterolemia

Corporate Comm India (CCI Newswire)